Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Supply Chain Development in Orthopaedics - OMTEC 2012 Opening Panel Discussion

The State and Future of the Orthopaedic Industry:
A High Altitude View
(Part 4 of 6) 


Supply Chain Development in Orthopaedics

"What are the key overall trends for orthopaedic suppliers?"

"Does the volume of inventory that OEMs keep onhand have a direct impact on the supply base?"

"Do offshore manufacturing facilities affect OEM make vs. buy decisions?"

"Does the investment community pay attention to the supply segment of orthopaedics?"

"Is there a future for small suppliers in orthopaedics?"

                                    

 

In response to unresolved challenges facing the orthopaedic industry (e.g. global economic turmoil, slowing markets, inflation, market consolidation, etc.), the 2012 OMTEC Opening Panel Discussion sought to extract actionable advice and insight from respected industry leaders on how to translate today’s issues into relatable language, and then prepare to act. Panel members represented select sectors from the orthopaedic supply chain, including:


Moderator:
David Floyd, Chief Executive Officer, OrthoWorx


Panelists:
Bill Plovanic
, Managing Director – Medical Devices Analyst, Canaccord Genuity, Inc.
Bill Kolter
, Corporate Vice President of Government Affairs and Corporate Communication, Biomet Orthopedics, Inc.
Brian Moore
, Former Chief Executive Officer, Symmetry Medical, Inc. and current CEO of A Day With A CEO

To view the remaining parts from the OMTEC 2012 - Opening Panel Discussion, please follow the below links:

Part 1: Market Growth Rates in Orthopaedics

Part 2: Medical Device Excise Tax

Part 3 Trends in Innovation and R&D Investment

Part 5: FDA - The Fly in the Ointment

Part 6: The Orthopaedic Industry in Five Years 


4 COMMENTS

Security code
Refresh